Conference
Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure
Abstract
Abstract
BACKGROUND
Authors
Kim DDH; Savoie ML; Bence-Bruckler I; Huebsch LB; Lalancette M; Hillis CM; Walker I; Forrest DL; Lipton JH
Volume
128
Publisher
American Society of Hematology
Publication Date
December 2, 2016
DOI
10.1182/blood.v128.22.1907.1907
Conference proceedings
Blood
Issue
22
ISSN
0006-4971